New data for Roche’s Hemlibra reinforce safety profile in people with haemophilia A
Roche announced results from the final analysis of the phase IIIb STASEY study, which confirm the favourable safety profile of Hemlibra (emicizumab), consistent with the phase III HAVEN…
Read More...
Read More...